Response to treatment series: part 2, tumor response assessment--using new and conventional criteria.

OBJECTIVE Conventional anatomic imaging biomarkers, including World Health Organization (WHO) criteria and Response Evaluation Criteria in Solid Tumors (RECIST), although effective, have limitations. This article will discuss the conventional and newer morphologic imaging biomarkers for the assessment of tumor response to therapy. CONCLUSION Applying established methods of assessing tumor response to therapy allows consistency in image interpretation and facilitates communication with oncologists. Because of the new methods of treatment, assessment of necrosis and volumetric information will need to be incorporated into size-based criteria.

[1]  Sigrid Stroobants,et al.  Revised response criteria for malignant lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  R. Salem,et al.  Does multidetector CT attenuation change in colon cancer liver metastases treated with 90Y help predict metabolic activity at FDG PET? , 2010, Radiology.

[3]  Richard C. Pais,et al.  Comparison of treatment response classifications between unidimensional, bidimensional, and volumetric measurements of metastatic lung lesions on chest computed tomography. , 2004, Academic radiology.

[4]  H. Rhim,et al.  Imaging after radiofrequency ablation of hepatic tumors. , 2009, Seminars in ultrasound, CT, and MR.

[5]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[6]  R. Wahl,et al.  From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors , 2009, Journal of Nuclear Medicine.

[7]  L. Zijp,et al.  Pretreatment probability model for predicting outcome after intraarterial chemoradiation for advanced head and neck carcinoma , 2004, Cancer.

[8]  I. Tannock,et al.  Influence of measurement error on assessment of response to anticancer chemotherapy: proposal for new criteria of tumor response. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  N. Obuchowski.  How many observers are needed in clinical studies of medical imaging? , 2004, AJR. American journal of roentgenology.

[10]  M. Makuuchi,et al.  Response Evaluation Criteria in Cancer of the Liver (RECICL) proposed by the Liver Cancer Study Group of Japan (2009 Revised Version) , 2010, Hepatology research : the official journal of the Japan Society of Hepatology.

[11]  Haesun Choi,et al.  We should desist using RECIST, at least in GIST. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  B. V. Van Beers,et al.  Biomarkers in abdominal imaging , 2009, Abdominal Imaging.

[13]  K. Engels,et al.  Prognostic relevance of volumetric analysis in tumour specimens of hypopharyngeal cancer , 2007, Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery.

[14]  Constantine Gatsonis,et al.  Response to treatment series: part 1 and introduction, measuring tumor response--challenges in the era of molecular medicine. , 2011, AJR. American journal of roentgenology.

[15]  Jianhua Jin,et al.  Response of liver metastases after treatment with yttrium-90 microspheres: role of size, necrosis, and PET. , 2007, AJR. American journal of roentgenology.

[16]  L. Schwartz,et al.  How to assess anti-tumour efficacy by imaging techniques. , 2008, European journal of cancer.

[17]  J. Radford,et al.  Response evaluation in gastrointestinal stromal tumours treated with imatinib: misdiagnosis of disease progression on CT due to cystic change in liver metastases. , 2006, The British journal of radiology.

[18]  S Saini,et al.  Tumour size measurement in an oncology clinical trial: comparison between off-site and on-site measurements. , 2003, Clinical radiology.

[19]  S. Monfardini,et al.  Recent progress in target therapy in colorectal cancer. , 2006, Anticancer research.

[20]  L. Schwartz,et al.  Imaging response assessment in oncology , 2006, Cancer imaging : the official publication of the International Cancer Imaging Society.

[21]  Shetal N Shah,et al.  Assessing tumor response and detecting recurrence in metastatic renal cell carcinoma on targeted therapy: importance of size and attenuation on contrast-enhanced CT. , 2010, AJR. American journal of roentgenology.

[22]  E. Halpern,et al.  CT tumor measurement for therapeutic response assessment: comparison of unidimensional, bidimensional, and volumetric techniques initial observations. , 2002, Radiology.

[23]  F. Miller,et al.  Tumor response after yttrium-90 radioembolization for hepatocellular carcinoma: comparison of diffusion-weighted functional MR imaging with anatomic MR imaging. , 2008, Journal of vascular and interventional radiology : JVIR.

[24]  F. Miller,et al.  Imaging of hepatocellular carcinoma after treatment with yttrium-90 microspheres. , 2007, AJR. American journal of roentgenology.

[25]  J. Haanen,et al.  Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib , 2010, British Journal of Cancer.

[26]  J. Dickson,et al.  Prediction of clinical outcome in treated neuroendocrine tumours of carcinoid type using functional volumes on 111In-pentetreotide SPECT imaging , 2004, Nuclear medicine communications.

[27]  O. Bouché,et al.  Imaging techniques to evaluate the response to treatment in oncology: current standards and perspectives. , 2009, Critical reviews in oncology/hematology.

[28]  C. Sawyers.  The cancer biomarker problem , 2008, Nature.

[29]  Binsheng Zhao,et al.  Evaluating variability in tumor measurements from same-day repeat CT scans of patients with non-small cell lung cancer. , 2009, Radiology.

[30]  A. Benson,et al.  Imaging response in the primary index lesion and clinical outcomes following transarterial locoregional therapy for hepatocellular carcinoma. , 2010, JAMA.

[31]  Eric P Tamm,et al.  CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings. , 2004, AJR. American journal of roentgenology.

[32]  D. DeMets,et al.  Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework , 2001, Clinical pharmacology and therapeutics.

[33]  Bachir Taouli,et al.  Assessment of tumor necrosis of hepatocellular carcinoma after chemoembolization: diffusion-weighted and contrast-enhanced MRI with histopathologic correlation of the explanted liver. , 2009, AJR. American journal of roentgenology.

[34]  C. Claussen,et al.  Comparison of different tumor response criteria in patients with hepatocellular carcinoma after systemic therapy with the multikinase inhibitor sorafenib. , 2011, Academic radiology.

[35]  Hirofumi Fujii,et al.  Radiologic measurements of tumor response to treatment: practical approaches and limitations. , 2008, Radiographics : a review publication of the Radiological Society of North America, Inc.

[36]  A. D. Van den Abbeele,et al.  Revised RECIST guideline version 1.1: What oncologists want to know and what radiologists need to know. , 2010, AJR. American journal of roentgenology.

[37]  E. Eisenhauer,et al.  RECIST revisited: a review of validation studies on tumour assessment. , 2006, European journal of cancer.

[38]  F. Miller,et al.  Multimodality imaging following 90Y radioembolization: a comprehensive review and pictorial essay. , 2008, Radiographics : a review publication of the Radiological Society of North America, Inc.

[39]  S Saini,et al.  Radiologic measurement of tumor size in clinical trials: past, present, and future. , 2001, AJR. American journal of roentgenology.

[40]  Riccardo Lencioni,et al.  Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma , 2010, Seminars in liver disease.

[41]  Bernd Turowski,et al.  CT-Based Evaluation of Tumor Volume After Intra-Arterial Chemotherapy of Locally Advanced Carcinoma of the Oral Cavity: Comparison with Clinical Remission Rates , 2005, CardioVascular and Interventional Radiology.

[42]  Heinz-Otto Peitgen,et al.  Informatics in radiology (infoRAD): new tools for computer assistance in thoracic CT part 2. Therapy monitoring of pulmonary metastases. , 2005, Radiographics : a review publication of the Radiological Society of North America, Inc.

[43]  Sang Min Lee,et al.  Usefulness of CT volumetry for primary gastric lesions in predicting pathologic response to neoadjuvant chemotherapy in advanced gastric cancer , 2009, Abdominal Imaging.

[44]  Fritz Schick,et al.  Image-guided radiofrequency ablation of renal cell carcinoma , 2007, European Radiology.

[45]  J. Bruix,et al.  Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma , 2004, Hepatology.

[46]  E. Eisenhauer,et al.  Review of phase II trial designs used in studies of molecular targeted agents: outcomes and predictors of success in phase III. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[48]  S. Sleijfer,et al.  Drug Insight: gastrointestinal stromal tumors (GIST)—the solid tumor model for cancer-specific treatment , 2008, Nature Clinical Practice Oncology.

[49]  L Pagliaro,et al.  Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. , 2001, Journal of hepatology.

[50]  A. Miller,et al.  Reporting results of cancer treatment , 1981, Cancer.

[51]  P. Workman,et al.  Biomarker-Driven Early Clinical Trials in Oncology: A Paradigm Shift in Drug Development , 2009, Cancer journal.

[52]  E. Aboagye,et al.  Monitoring Predominantly Cytostatic Treatment Response with 18F-FDG PET , 2009, Journal of Nuclear Medicine.

[53]  H. Kauczor,et al.  [Follow-up CT measurement of liver malignoma according to RECIST and WHO vs. volumetry]. , 2007, RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin.

[54]  V. Dicken,et al.  Semi-automated volumetric analysis of lymph node metastases in patients with malignant melanoma stage III/IV-A feasibility study , 2008, European Radiology.

[55]  David A Bluemke,et al.  Unresectable hepatocellular carcinoma: serial early vascular and cellular changes after transarterial chemoembolization as detected with MR imaging. , 2009, Radiology.

[56]  Jordi Rimola,et al.  Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma , 2009, Cancer.

[57]  Filippo Cademartiri,et al.  Imaging for oncologic staging and follow-up: review of current methods and novel approaches. , 2008, Acta bio-medica : Atenei Parmensis.

[58]  M. Mulcahy,et al.  Morphological Analysis of Pancreatic Adenocarcinoma on Multidetector Row Computed Tomography: Implications for Treatment Response Evaluation , 2009, Pancreas.

[59]  W. Heindel,et al.  Volumetric measurements of pulmonary nodules at multi-row detector CT: in vivo reproducibility , 2003, European Radiology.

[60]  V. Torri,et al.  High-grade soft-tissue sarcomas: tumor response assessment--pilot study to assess the correlation between radiologic and pathologic response by using RECIST and Choi criteria. , 2009, Radiology.

[61]  H. Winer-Muram,et al.  Lung tumor growth: assessment with CT--comparison of diameter and cross-sectional area with volume measurements. , 2004, Radiology.

[62]  A. D. Van den Abbeele,et al.  Gastrointestinal stromal tumor: new nodule-within-a-mass pattern of recurrence after partial response to imatinib mesylate. , 2005, Radiology.

[63]  Annick D. Van den Abbeele,et al.  The Lessons of GIST—PET and PET/CT: A New Paradigm for Imaging , 2008 .

[64]  E. Rummeny,et al.  Adenocarcinomas of esophagogastric junction: multi-detector row CT to evaluate early response to neoadjuvant chemotherapy. , 2006, Radiology.

[65]  H. Rhim,et al.  Spectrum of CT findings after radiofrequency ablation of hepatic tumors. , 2008, Radiographics : a review publication of the Radiological Society of North America, Inc.

[66]  J E Husband,et al.  Evaluation of the response to treatment of solid tumours – a consensus statement of the International Cancer Imaging Society , 2004, British Journal of Cancer.

[67]  Lineke van der Weide,et al.  Early detection of local RFA site recurrence using total liver volume perfusion CT initial experience. , 2009, Academic radiology.

[68]  Geert Molenberghs,et al.  Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis , 2000, The Lancet.

[69]  C. Jaffe.  Measures of response: RECIST, WHO, and new alternatives. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[70]  D. Bluemke,et al.  Role of diffusion-weighted imaging in estimating tumor necrosis after chemoembolization of hepatocellular carcinoma. , 2003, AJR. American journal of roentgenology.

[71]  Greg Yothers,et al.  Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. , 2005, The New England journal of medicine.

[72]  A. Benson,et al.  Role of the EASL, RECIST, and WHO response guidelines alone or in combination for hepatocellular carcinoma: radiologic-pathologic correlation. , 2011, Journal of hepatology.

[73]  Rolf W. Günther,et al.  Semi-Automated Quantification of Hepatic Lesions in a Phantom , 2009, Investigative radiology.

[74]  M. Mack,et al.  Usefulness of MRI volumetric evaluation in patients with squamous cell cancer of the head and neck treated with neoadjuvant chemotherapy , 2007, Head & neck.

[75]  M. Abecassis,et al.  Radiologic–pathologic correlation of hepatocellular carcinoma treated with internal radiation using yttrium‐90 microspheres , 2009, Hepatology.

[76]  D. V. Von Hoff,et al.  Measure once or twice -- does it really matter? , 1999, Journal of the National Cancer Institute.